Brind.
  1. Ensysce Biosciences is developing novel opioid candidates, including PF614, aimed at treating pain and addressing the opioid addiction epidemic.

Brad Sorensen published a research report on Ensysce Biosciences' efforts to develop pain relief for the American public.

1 report, 1 independent Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Brad Sorensen published a research report on Ensysce Biosciences' efforts to develop pain relief for the American public.

Who's involved

What this event is mainly about
Ensysce BiosciencesBrad Sorensen

Keep exploring

Part of

Ensysce Biosciences is developing novel opioid candidates, including PF614, aimed at treating pain and addressing the opioid addiction epidemic. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Zacks Small Cap ResearchENSC Start Phase 3 Trial on Abuse-Resistant Pain Reliever By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is de